MIDAZOLAM INJECTION 5 MG — DIN 02423766
MIDAZOLAM : 5 MG · PFIZER CANADA ULC · SOLUTION · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is MIDAZOLAM INJECTION?
MIDAZOLAM INJECTION 5 MG contains MIDAZOLAM : 5 MG. It is listed in the Health Canada Drug Product Database under DIN 02423766, held by PFIZER CANADA ULC, supplied as SOLUTION for INTRAMUSCULAR ; INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 21-May-2021. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is MIDAZOLAM INJECTION used for?
Intramuscular premedication; intravenous sedation/anxiolysis/amnesia for short procedures; induction of anesthesia; continuous infusion for sedation in ICU.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Midazolam cost around the world?
Midazolam is listed on 19 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Bahrain publishes a retail (max); Brazil publishes a preco fabrica (ex-factory ceiling). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| South Africa | single exit price | 22 | 29 | ZAR███.██ |
| United States | acquisition | 5 | 18 | USD███.██ |
| Brazil | preco fabrica (ex-factory ceiling) | 5 | 16 | BRL███.██ |
| Czechia | max producer price (ex-factory) | 5 | 16 | CZK███.██ |
| Romania | max producer price | 11 | 15 | RON███.██ |
| Saudi Arabia | public | 11 | 15 | SAR███.██ |
| Sweden | AIP (pharmacy purchase price) | 2 | 10 | SEK███.██ |
| Australia | ex-manufacturer | 2 | 9 | AUD███.██ |
| Italy | prezzo al pubblico (classe A) | 8 | 8 | EUR███.██ |
| Italy | ex-factory (classe H) | 6 | 8 | EUR███.██ |
| United Kingdom | hospital | 7 | 7 | GBP███.██ |
| Greece | producer price (ex-factory) | 7 | 7 | EUR███.██ |
| United Arab Emirates | public | 5 | 5 | AED███.██ |
| Morocco | PPV (public price) | 3 | 5 | MAD███.██ |
| Norway | max AUP (pharmacy retail) | 2 | 5 | NOK███.██ |
| Spain | PVP con IVA (public price) | 4 | 4 | EUR███.██ |
| Hungary | producer price (ex-factory) | 4 | 4 | HUF███.██ |
| Luxembourg | reimbursement | 4 | 4 | EUR███.██ |
| Slovakia | categorised final price | 4 | 4 | EUR███.██ |
| Bahrain | retail (max) | 1 | 2 | BHD███.██ |
191 pack listings across 118 brand entries and 18 price bases, refreshed 08 Sep 2026. Ranges span every Midazolam pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Midazolam in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
13 holders have a Canadian DIN containing Midazolam, across 32 DINs, of which 14 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| PFIZER CANADA ULC | 6 | 4 | MIDAZOLAM INJECTION, MIDAZOLAM INJECTION USP | Sourceable in Canada |
| NEURAXPHARM PHARMACEUTICALS, S.L. | 4 | 4 | BUCCOLAM | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 4 | 2 | MIDAZOLAM INJECTION, MIDAZOLAM INJECTION SDZ | Sourceable in Canada |
| FRESENIUS KABI CANADA LTD | 2 | 2 | MIDAZOLAM INJECTION, USP | Sourceable in Canada |
| HIKMA CANADA LIMITED | 1 | 1 | MIDAZOLAM INJECTION USP | Sourceable in Canada |
| STERINOVA INC. | 1 | 1 | MIDAZOLAM INJECTION USP | Sourceable in Canada |
| APOTEX INC | 2 | 0 | APO-MIDAZOLAM INJECTABLE 1 MG/ML, APO-MIDAZOLAM INJECTABLE 5 MG/ML | No marketed DIN |
| BAXTER CORPORATION | 2 | 0 | MIDAZOLAM INJECTION, USP | No marketed DIN |
| HOFFMANN-LA ROCHE LIMITED | 2 | 0 | VERSED INJ 1MG/ML, VERSED INJ 5MG/ML | No marketed DIN |
| HOSPIRA HEALTHCARE ULC | 2 | 0 | MIDAZOLAM INJECTION BP | No marketed DIN |
| MYLAN PHARMACEUTICALS ULC | 2 | 0 | MIDAZOLAM INJECTION | No marketed DIN |
| PHARMASCIENCE INC | 2 | 0 | PMS-MIDAZOLAM | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 5 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAMUSCULAR ; INTRAVENOUS |
| Pack configuration (monograph) | Available in 5 mg/mL, 15 mg/3 mL, 5 mg/5 mL, and 50 mg/10 mL formats. |
| Storage | Not explicitly stated in provided text (standard practice is 15-30°C). |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Midazolam |
|---|---|
| ATC code | N05CD08 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02423766 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2423766 |
| Brand name | MIDAZOLAM INJECTION |
| Generic / active ingredient | MIDAZOLAM : 5 MG |
| Market authorization holder | PFIZER CANADA ULC |
| Health Canada schedule | TARGETED SUBSTANCES (CDSA IV) |
| ATC code | N05CD08 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N05CD |
| Current status | CANCELLED POST MARKET |
| Status date | 21-May-2021 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Adult sedation: initial dose 1-2.5 mg, titrate slowly over 2-3 mins. Pediatric: dose on mg/kg basis. ICU: continuous infusion titrated to effect. Do not use rapid bolus in neonates.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to benzodiazepines; acute pulmonary insufficiency; severe chronic obstructive pulmonary disease; acute narrow angle glaucoma.
Warnings and precautions
Risk of respiratory depression/arrest. Use only with continuous monitoring and resuscitation equipment. Avoid in shock, coma, or acute alcohol intoxication. Risk of physical/psychological dependence.
Is Midazolam in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by FRESENIUS KABI CANADA LTD, last seen 09 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
14 of 32 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| BUCCOLAM | 2.5 MG / 0.5 ML | SOLUTION | NEURAXPHARM PHARMACEUTICALS, S.L. | MARKETED | 02559579 |
| BUCCOLAM | 5 MG / 1 ML | SOLUTION | NEURAXPHARM PHARMACEUTICALS, S.L. | MARKETED | 02559587 |
| BUCCOLAM | 7.5 MG / 1.5 ML | SOLUTION | NEURAXPHARM PHARMACEUTICALS, S.L. | MARKETED | 02559595 |
| BUCCOLAM | 10 MG / 2 ML | SOLUTION | NEURAXPHARM PHARMACEUTICALS, S.L. | MARKETED | 02559609 |
| MIDAZOLAM INJECTION | 1 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | 02240285 |
| MIDAZOLAM INJECTION | 5 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | 02240286 |
| MIDAZOLAM INJECTION USP | 1 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | 02382342 |
| MIDAZOLAM INJECTION USP | 1 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | 02382377 |
| MIDAZOLAM INJECTION USP | 5 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | 02382350 |
| MIDAZOLAM INJECTION USP | 1 MG | SOLUTION | HIKMA CANADA LIMITED | MARKETED | 02553104 |
2 · Same class — other molecules in ATC N05CD
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Midazolam | APO-MIDAZOLAM INJECTABLE 1 MG/ML · APO-MIDAZOLAM INJECTABLE 5 MG/ML · BUCCOLAM · MIDAZOLAM INJECTION · +7 more | 32 | 14 | Yes |
| Temazepam | APO-TEMAZEPAM · CO TEMAZEPAM CAPSULES 15MG · CO TEMAZEPAM CAPSULES 30MG · DOM-TEMAZEPAM · +14 more | 28 | 2 | Yes |
| Flurazepam | BIO-FLURAZEPAM · DALMANE · FLURAZEPAM · FLURAZEPAM 15 · +12 more | 20 | 2 | Yes |
| Nitrazepam | APO-NITRAZEPAM · MOGADON · NITRAZADON · NITRAZEPAM-10 · +2 more | 10 | 2 | Yes |
| Triazolam | ALTI-TRIAZOLAM TAB 0.125MG · ALTI-TRIAZOLAM TAB 0.25MG · HALCION · MYLAN-TRIAZOLAM · +8 more | 16 | 1 | Yes |
| Estazolam | PROSOM TAB 1MG · PROSOM TAB 2MG | 2 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC N05C
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| N05CF | Eszopiclone · Zaleplon · Zolpidem · Zopiclone | 125 | 57 |
| N05CM | Dexmedetomidine · Ethchlorvynol · Scopolamine · Valerianae Radix | 31 | 11 |
| N05CC | Chloral Hydrate · Paraldehyde | 9 | 1 |
| N05CJ | Daridorexant · Suvorexant | 6 | 1 |
| N05CA | Amobarbital · Barbiturates, Plain · Pentobarbital · Secobarbital | 14 | 0 |
| N05CB | Combinations Of Barbiturates | 2 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is MIDAZOLAM INJECTION called?
The same molecule, Midazolam, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| BUCCOLAM | Latin | Czechia, Sweden |
| Dormicum | Latin | Czechia, Morocco, South Africa |
| MIDAZOLAM | Latin | Brazil |
| Midazolam Kalceks | Latin | Bahrain, Czechia, Saudi Arabia |
| Zyamis | Latin | Australia |
| Midanium | Latin | Morocco, South Africa |
| MIDAZOLAM ACCORD | Latin | Czechia |
| Midazolam Medical Valley | Latin | Sweden |
| Midazolam Panpharma | Latin | Norway |
| DORMIUM | Latin | Brazil |
| MIDAZOLAM HAMELN | Latin | Czechia |
| DORMONID | Latin | Brazil |
| Oroxelam | Latin | Saudi Arabia |
| HYPOZAM | Latin | Brazil |
| Micro-Midazolam | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.